Journal of Young Pharmacists logo
Submit
Journal of Young PharmacistsACADEMIC PUBLISHING
Article

Dry Powder Inhaler Formulation of Remdesivir Mucoadhesive Nanoparticle for Respiratory Diseases

1★, 1,2, 2★ Corresponding author

  1. 1School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry, INDIA.
  2. 2Surya School of Pharmacy, Surya Group of Institutions, Vikravandi, Villupuram, Tamil Nadu, INDIA.

CORRESPONDENCE

Venugopal Vijayan

School of Pharmacy, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry, INDIA.

vijayanv2@gmail.com

Received: 22-09-2023; Revised: 30-09-2023; Accepted: 24-06-2024.

Volume 16, Issue 4 · pp. 753-761 · 2024 · DOI: 10.5530/jyp.2024.16.95

ABSTRACT

Background: Remdesivir is a antiviral drug, which has approved in COVID-19 pandemic as emergency use. In order to solubilize the remdesivir in injection form, Sulfobutylether-Beta- Cyclodextrin (SBECD) is used as solubility enhancer. Since SBECB is excreted by the kidney and it is contradicted for patients with severe renal impairment.Objectives: This research aim to formulate and evaluate the dry powder inhaler formulation of remdesivir mucoadhesive nanoparticle for respiratory diseases.Materials and Methods: The nanoparticle was prepared by nanoprecipitation method using PLGA and Chitosan, the prepared nanoparticle was subjeted to various studies include physiochemical characterization, mucoadhesive properties. The formulation has loaded in Dry Powder Inhaler (DPI) and evaluated its dispensing properties.Results: The prepared nanoparticle has spherical shape with 104.6 nm in size and zeta potential of -12.7 mV. The nanoparticle has 72.06% of entrapment efficiency with significant in sustained drug release of 85.1% at 48 hr. The mucoadhesive nanoparticle showed negligible damage in epithelial integrity with DPI emitted dose of 87.02% and MMAD of 2.90 μm. The prepared nanoparticle showed significant mucoadhesive strength of 77.1% with lungs mucosa.Conclusion: Based on the above studies, remdesivir mucoadhesive nanoparticle deliver through DPI, it could be the best alternative route of administration during emergency situation.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Vijayan, V., Ravindran, S., & Sockalingam, A. (2024). Dry Powder Inhaler Formulation of Remdesivir Mucoadhesive Nanoparticle for Respiratory Diseases. Journal of Young Pharmacists, 16(4), 753-761. https://doi.org/10.5530/jyp.2024.16.95

    Copyright and licence

    © 2024 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0